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Purpose: We tested the hypothesis that genetic variants in vasoactive and angiogenic factors regulating the retina
vasculature contribute to the development of diabetic retinopathy (DR).
Methods: A case-control study was performed to study the genetic association between DR and polymorphic variants of
EDN1 (Lys198Asn), LTA (IVS1–80C>A, IVS1–206G>C, IVS1–252A>G), eNOS (Glu298Asp), and ITGA2 (BgI II) in a
Chinese population with type 2 diabetes mellitus. A well defined population with type 2 diabetes, consisting of 127 controls
and 216 DR patients, was recruited.
Results: A higher frequency of the Asn/Asn genotype of EDN1 was found in individuals with at least 10 years of diabetes
and no retinopathy (controls) compared with DR patients with any duration of diabetes (DR: 2.3%; control: 11.0%;
p=0.0002). The Asn allele was also more frequent in controls than DR patients (DR: 16.4%; control: 29.5%; p=0.007).
Multiple logistic regression analysis showed that the Asn/Asn genotype was the factor most significantly associated with
reduced risk of DR (odds ratio=0.19; 95% CI: 0.07-0.53; p=0.002) and with late onset of diabetes (Asn/Asn: 59 years;
Lys/Lys + Lys/Asn: 53 years; p=0.02). Moreover, the Lys/Lys genotype was more common among patients with
nonproliferative (75.7%) than proliferative DR (56.9%; p=0.008). The distributions of Lys198Asn alleles in hypertension
did not differ from normotensive subjects. No associations between DR and polymorphisms of LTA, eNOS, or ITGA2
were detected, and there were no detectable gene-gene or gene-environmental interactions among the polymorphisms.
Conclusions: The Asn/Asn genotype of EDN1 was associated with a reduced risk of DR and with delayed onset of type
2 diabetes.
Diabetic retinopathy (DR), a leading cause of blindness
worldwide,  is  a  microvascular  complication  of  diabetes
characterized  by  increased  vascular  permeability  and
hemostatic  abnormalities  which  can  eventually  lead  to
vascular occlusion in spite of antidiabetic treatment and result
in  retinal  nonperfusion  and  neovascularization  [1].  DR  is
associated with disorders in the nitric oxide (NO) pathway,
including  impaired  NO-mediated  vasodilation,  increased
oxidative and nitrative stress, dysregulation of NO synthase
isoforms,  and  endothelial  NO  synthase  uncoupling  [2].
Clinically, DR can be classified into two major categories:
early  and  advanced.  Early  stage  of  DR,  also  called
nonproliferative  diabetic  retinopathy  (NPDR),  is
characterized by edema, leakage of fluid, and limited blood
flow  into  the  eye.  But  NPDR  has  no  abnormal
neovascularization.  The  advanced  stage  of  DR,  or
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proliferative  diabetic  retinopathy  (PDR),  involves
neovascularization and fibrous tissue formation [3].
Over 30 candidate genes involved in different metabolic
mechanisms and functional pathways have been reported to
be associated with DR [4,5]. However, only a fraction of them
have shown consistent associations with occurrence of DR or
its severity in different studies [4,5]. The (CA)n microsatellite
marker at the 5’-end of the aldose reductase (AR2) gene is the
most  frequently  reported  polymorphism  that  is  associated
with DR [4]. Results of our previous study on Chinese DR
patients  showed  that  the  z-2  allele  of  the  5′-(CA)n
polymorphism was independently associated with DR in type
2  diabetes  [6].  Genetic  studies  have  been  conducted  for
vasoactive  and  angiogenic  factors  to  explore  their
contributions to DR, such as endothelial nitric oxide synthase
(eNOS),  lymphotoxin-a  (LTA),  integrin  alpha-2  (ITGA2),
angiotensin converting enzyme (ACE), vascular endothelial
growth  factor  (VEGF),  intercellular  adhesion  molecule  1
(ICAM or CD45), β3-adrenergic receptor gene (ADRB3), and
endothelin-1 (EDN1) [4,5]. However, results for some of these
genes, such as ACE and CD45, have been inconsistent in
various  ethnic  groups  and  different  study  populations.
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1698Discrepancies among these studies are likely due to variations
in case definition, sample sizes, and medical conditions of
control subjects. Some studies selected normal individuals as
controls instead of diabetic subjects without DR. Thus, the
comparisons  were  only  between  normal  individuals  and
diabetic  individuals,  which  may  lead  to  identification  of
genetic  variants  associated  with  vulnerability  to  diabetes
mellitus (DM) rather than to DR [7].
In this study, we focused on a well-defined population
with type 2 diabetes. Only patients without DR but with DM
for  at  least  10  years  were  selected  as  controls.  We
hypothesized  that  genetic  variants  in  vasoactive  and
angiogenic factors which regulate the retina vasculature might
contribute  to  the  development  of  retinopathy.  We  chose
polymorphisms  previously  reported  to  have  positive
association  with  DR,  but  none  have  been  evaluated  in  a
Chinese DM population. The Lys198Asn polymorphism of
EDN1  was  also  studied  because  it  is  associated  with
hypertension,  which  is  a  risk  factor  of  DR  [8-11].  We
examined six polymorphisms in four genes, including two
vasoactive genes, EDN1 and eNOS, and two hemodynamic
blood flow related genes, LTA and ITGA2. They have been
reported to be associated with vascular diseases in different
populations.
METHODS
Study subjects: Unrelated participants with type 2 noninsulin-
dependent diabetes mellitus (NIDDM) were recruited from
the Eye Clinic of the Prince of Wales Hospital, Hong Kong.
Diagnosis of type 2 diabetes was based on WHO criteria
[12]. This study was performed in accordance with the ethics
standards set by the Declaration of Helsinki. Approval for use
of human subjects was obtained from the New Territories East
Cluster,  Hong  Kong,  clinical  research  ethics  committee.
Informed consent was obtained from the participants after
explanation of the nature and possible consequences of the
study. DR was diagnosed in a masked manner by independent
ophthalmologists by direct ophthalmoscope through dilated
pupils. Patients with no signs of DR and with known DM
duration <10 years were excluded. Patients without DR but
with diabetes duration ≥10 years were designated as control
subjects (DM). Diabetic patients with DR were defined as case
subjects (DR) either of the NPDR or PDR subtype according
to  Early  Treatment  Diabetic  Retinopathy  Study  (ETDRS)
criteria [13]. Documented information included age, sex, age
at onset of diabetes, duration of diabetes, fast plasma glucose
and hemoglobin A1c (HbA1c) level, age at onset of DR, family
history,  and  treatment  details.  A  smoker  was  defined  as
someone who smoked at least five cigarettes daily for more
than one year. Onset of DR was defined as the first ever
documentation of the clinical evidence of DR on the chart.
Hyperlipidemia  was  diagnosed  on  patients  with  either
elevated total cholesterol (>6.2 mM) or elevated triglycerides
(>1.7  mM)  requiring  either  lifestyle  modification  or
pharmacological intervention. Renal failure was defined as
persistent and irreversible derangement of the renal function
test,  typically  creatinine  >80  μM  upon  consecutive
measurements.
After exclusion of non-DR patients having DM duration
of fewer than 10 years, 343 patients were enrolled, consisting
of  127  controls  and  216  DR  patients.  Using  the  allele
distributions in non-DR patients, we calculated the statistical
power at 80% with a Bonferroni correction significance level
of 0.0083, where six comparisons were made, and α, before
correction was 0.05. Thus the corrected level, α ÷ 6 is 0.083
(two-sided) to detect an allele odds ratio of at least 2.2 for
eNOS or 1.8 for the other five polymorphisms. DR patients
were further divided into NPDR (n=144) and PDR (n=72).
DR  group  showed  a  significantly  higher  level  of  HbA1c
(7.35±1.36%  versus  6.9±1.91%,  p=0.046)  and  a  higher
percentage  of  patients  who  underwent  insulin  treatment
(11.5% versus 2.4%, p<0.00001) than control group (Table
1). The PDR group was slightly younger than NPDR and had
earlier onset of diabetes. Diabetic macular edema was more
common in PDR than in NPDR.
Genotyping: The whole blood specimens (5 ml) from all the
patients were collected in EDTA tube and stored at -20 °C for
fewer than two months’ storage. Genomic DNA was extracted
from  whole  blood  using  the  Qiamp  kit  (Qiagen,  Hilden,
Germany) and stored at −20 °C for fewer than two months
before analysis. The polymorphisms of EDN1 (Lys198Asn or
rs5370) and LTA (IVS1–80C>A, IVS1–206G>C, and IVS1–
252A>G) were detected by polymerase chain reaction (PCR)
and direct DNA sequencing. PCR was performed in a final
volume  of  25  μl  containing  2.5  μl  of  10X  PCR  buffer
(InvitrogenTM Life Technology, Carlsbad, CA), 0.3 μl of each
primer (EDN1: forward 5’- CTT TTG CCA AAG GGT GAT
TT-3’ and reverse 5’- AGG GTG GAG AGT GCA GAG
TC-3’; LTA: forward 5’- TCC TGC CCC ATC TCC TTG G-3’
and reverse 5’-AGA GAG AGA GAC AGT GAG CGG G-3'),
0.5  μl  of  10  mM  dNTP,  1  μl  of  50  mM  MgCl2,  0.5  U
AmpliTaq® DNA Polymerase (Applied Biosystems, Foster
City, CA), and 10 ng of DNA. After the initial denaturation at
94 °C for 3 min, 35 cycles were conducted: 94 °C for 30 s,
annealing for 30 s (EDN1: 54 °C; LTA: 58 °C), and 72 °C for
30  s.  The  final  extension  lasted  for  10  min  at  72  °C.
Sequencing was performed using a standard protocol on an
automated  3130X  DNA  sequencer  (Applied  Biosystems)
[14]. Sequence data were analyzed on computer (Chromas
ver. 2.13; Technelysium Pty Ltd., Tewantin, QLD, Australia)
and  compared  with  published  genes  sequences  from
Ensembl.  All  rare  variants  detected  were  confirmed  by
bidirectional sequencing.
Polymorphisms in eNOS (894G>T) and ITGA2 (IVS8–
1059T>C) were analyzed by PCR followed by BanII and
BgIII restriction analysis respectively [15,16]. To cross-check
the genotyping results, we randomly selected one-fourth of
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of results was obtained.
Statistical analysis: Differences in genotype distribution and
consistency with Hardy–Weinberg equilibrium were tested by
χ2 test. Continuous clinical data (age, age at onset of diabetes,
duration  of  diabetes,  and  HbA1c)  were  compared  by
independent Student t test, and categorical clinical data were
compared using the χ2 test or the Fisher’s exact test. Tukey’s
test was used for multiple Post Hoc comparisons, and the
Bonferroni  method  was  used  for  multiple  comparison
adjustment. To assess the role of gene polymorphisms and
search for gene-gene and gene-environmental interactions, we
built logistic regression models using various polymorphisms
and  clinical  parameters.  Disease  status  was  set  as  the
dependent  variable  (DR=1;  control=0),  and  gene
polymorphisms  and  environmental  factors  as  independent
variables.  A  stepwise  regression  approach  was  used  to
optimize the analysis. SPSS for Windows, standard version
11.5 (SPSS, Chicago, IL), was used. Statistical significance
was defined as p<0.05.
RESULTS
The distributions of the six polymorphisms of EDN1, eNOS,
LTA, and ITGA2 in both case and control groups were under
Hardy–Weinberg  equilibrium.  A  significantly  higher
frequency  of  the  EDN1  Asn/Asn  genotype  was  found  in
controls than in DR patients (11% versus 2.3%, p=0.0002,
Bonferroni corrected significance level 0.0083=0.05÷6, Table
2). The Asn allele frequency was also significantly higher in
controls than in the DR group (29.5% versus 16.4%, p=0.007,
Bonferroni corrected significance level 0.0083). For genotype
or  allele  distributions  of  eNOS,  IGTA2,  and  LTA
polymorphisms, there was no significant difference between
DM subjects with or without DR (Table 2).
For the EDN1 polymorphism, we compared DM controls
and DR subtypes. NPDR patients had a higher frequency of
Lys/Lys than either DM controls or PDR patients (75.7%
versus  either  56.9%  or  52.0%  with  p=0.0001  and  0.008,
respectively, Bonferroni corrected significance level 0.017 =
0.05  ÷  3),  but  PDR  did  not  differ  from  DM  controls
(p>Bonferroni corrected significance level 0.017). The Asn
allele frequency was also significantly higher in controls than
in  NPDR  (29.5%  versus  13.5%;  p=0.00005,  Bonferroni
corrected  significance  level  0.017).  However,  allele
frequencies did not significantly differ among DR subtypes.
Multivariable logistic regression analysis showed that
EDN1 Asn/Asn was an independent protective factor for DR
after adjustment for age, age at onset of diabetes and insulin
therapy. The Odds ratio (OR) was 0.19 with 95% confidence
interval (CI) ranging from 0.07 to 0.53 (p=0.002; Table 3).
The difference of Lys198Asn genotype distributions between
NPDR and PDR was not significant after adjusting for the age
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TABLE 1. CLINICAL AND METABOLIC CHARACTERISTICS OF PATIENTS WITH TYPE 2 DIABETES
  Characteristic
   DM                     All DR                  NPDR                     PDR
(n=127)                 (n=216)                 (n=144)                  (n=72)
Age (years) 68.8±11.2 66.8±10.4 69.1±9.4 62.7±11.04,5
Gender (% male) 60.6 60.6 59.4 62.5
Age at onset of DM (years) 53.8±11.9 53.0±10.8 55.4±10.4 48.4±10.06,7
Duration of diabetes (years) 14.7±4.8 13.9±8.3 13.7±8.0 14.4±8.8
Age at onset of DR (years) None 62.1±10.2 65.6±9.4 56.8±9.9
Gap between DR and DM onset ages (years) None 8.4±8.8 9.1±7.6 7.3±11.1
Duration of DR (years) None 4.9±3.8 4.6±3.6 5.6±4.1
HbA1c (%) 6.90±0.91 7.35±1.391 7.53±1.563 6.98±0.94
Fasting plasma glucose (mM) 8.24±1.98 8.26±2.83 8.09±2.86 8.81±2.89
Insulin use (% of patients) 2.4 11.52 8.3 18.18
Family history of DM (% of patients) 17.7 25.3 22.5 29.2
Hypertension (% of patients) 68.8 67.1 66 69.4
Hyperlipidemia (% of patients) 26.8 24.8 24.5 26.4
Renal failure (% of patients) 0.8 4.1 3.5 5.6
Current smoking (% of patients) 9.2 11.1 11.1 11.1
Diabetic macular edema (% of patients) None 31.9 26.4 43.19
The  table showed the comparisons of the clinical and metabolic characteristics among diabetes mellitus controls (DM) and
diabetic retinopathy (DR) and DR subtypes. All p values were computed by χ2 or student t-tests. DR group showed a significantly
higher level of HbA1c and higher percentage of patients receiving insulin treatment than controls (1: p=0.046; 2: p<0.00001).
By Tukey’s test for Post Hoc multiple comparisons (the Bonferroni corrected significance level was 0.025=0.05÷2), the
significant difference of HbA1c level was only found between nonproliferative diabetic retinopathy (NPDR) and controls (2:
p=0.001) and the significant higher percentage of the patients receiving insulin treatment was only due to proliferative diabetic
retinopathy (PDR) group (8: p=0.00009). The PDR group was slightly younger than NPDR (4: p=0.001) and controls (5:
p=0.00005) and with earlier onset of diabetes than other two groups (6: p=0.0008; 7: p=0.000003). The presence of diabetic
macular edema was evident in PDR compared to NPDR (9: p=0.001).at onset of diabetes (p>0.05). But age at onset of diabetes was
an independent factor associated with the PDR phenotype
(OR=0.94; 95% CI: 0.91–0.97; p=0.00001). We also found
no gene-gene or gene-environmental factor interaction in DM
samples (p>0.05). The age of DM onset of patients with the
Asn/Asn genotype was about six years later than patients with
other genotypes (p=0.02; Table 4). Genotype distributions of
Lys198Asn  were  not  different  between  hypertensive  and
nonhypertensive subjects (Table 4).
DISCUSSION
The vasodilator NO and vasoconstrictor endothelin-1 (ET-1)
effectively  determine  the  tone  of  blood  vessels  [2,17].
Changes  in  blood  flow  contribute  to  early  diabetic
microangiopathy in DR [18]. Genetic studies on eNOS and
risk to DR have shown inconsistent results, and no association
between polymorphisms in EDN1 and DR has been identified
[19-22]. LTA and ITGA2 are important molecules involved
in  lymphocyte  proliferation  and  platelet  adhesion  to
subendothelial  tissues.  They  are  essential  for  thrombus
formation and contribute to tissue ischemia and activation of
neovascularization  in  DR.  The  BgIII  polymorphism  of
ITGA2 has been shown to be strongly associated with DR in
the Caucasian and Japanese populations [16,23]. There are
also ethnic differences in the genetic risk of DR. LTA IVS1–
252A>G  has  been  found  to  be  associated  with  DR  in
Caucasians but not in Japanese [7,24].
Our study is the first to investigate the EDN1 Lys198Asn
polymorphism  in  a  diabetic  population.  The  Asn/Asn
frequency was reported to be 6.7% in the Chinese population
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TABLE 2. GENOTYPE AND ALLELE FREQUENCIES IN GROUPS WITH AND WITHOUT RETINOPATHY
  Polymorphism
Genotype distribution (%) Allele distribution (%)
DR subtypes DR subtypes
DM                  NPDR                PDR                               DM                NPDR
(n=127)                       (n=144)                           (n=72)                                               (n=254)                          (n=288)
PDR
(n=144)
EDN1 Lys198Asn                     Lys/Lys 66 (52.0) 109 (75.7) 41 (56.9) Lys 179 (70.5) 249 (86.5) 112 (77.8)
Lys/Asn 47 (37.0)           31 (21.5) 30 (41.7)         Asn 75 (29.5) 39 (13.5) 32 (22.2)
Asn/Asn 14 (11.0)             4 (2.8) 1 (1.4)
p value all DR versus DM: 0.0002 all DR versusDM: 0.007
NPDR versus DM: 0.0001 NPDR versus DM: 0.00005
PDR versus NPDR: 0.008
eNOS Glu298Asp Glu/Glu 98 (77.2) 110 (76.9) 55 (76.4) Glu 224 (88.2) 249 (87.1) 127 (88.2)
Glu/Asp 28 (22.0)            29 (20.3) 17 (23.6)        Asp 30 (11.8)    39 (12.9)             17 (11.8)
Asp/Asp 1 (0.8)                4 (2.8)              0 (0)
ITGA2 BgI II BgI II (-/-) 65 (51.2)             76 (52.8)         33 (45.8)           - 184 (72.4)          211(73.3) 100 (69.4)
BgI II (-/+) 54 (42.5) 59 (41.0)         34 (47.2)          + 70 (27.6) 77 (26.7) 44 (30.6)
BgI II (+/+) 8 (6.3) 9 (6.3) 5 (6.9 )
LTA IVS1-80C>A CC 64 (50.4)             76 (53.1)          31 (43.7) C 174 (68.5)          210 (73.4) 94 (66.2)
CA 46 (36.2) 58 (40.6) 32 (45.1)          A 80 (31.5) 76 (26.6) 48 (33.8)
AA 17 (13.4)               9 (6.3)              8 (11.3)
LTA IVS1-252A>G AA 31 (24.4)             30 (20.8)          19 (26.4) A 127 (50.0) 134 (46.5) 71 (49.3)
GA 65 (51.2) 74 (51.4) 33 (45.8)          G 127 (50.0) 154 (53.2) 73 (50.7)
GG 31 (24.4) 40 (27.8) 20 (27.8)
LTA IVS1-206G>C GG                  63 (49.6)             76 (52.8)          34 (47.2) G 173 (68.1) 210 (72.9) 101 (70.1)
GC 47 (37.0)             58 (40.3) 33 (45.8)          C 81 (31.9) 78 (27.1) 43 (29.9)
CC 17(13.4) 10 (6.9)              5 (6.9)
The genotype and allele frequency distributions are shown for diabetic retinopathy (DR) and controls (diabetes mellitus without
diabetic  retinopathy, DM). Only the endothelin-1 (EDN1) Lys198Asn genotype and its allele distributions showed a statistically
significant difference between DR patients and controls at the Bonferroni corrected significance level of 0.0083=0.05÷6. For
comparing  DR  subtypes  and  DM  distributions  of  only  the EDN1   Lys198Asn  polymorphism,  the  Bonferroni  corrected
significance level was 0.017=0.05÷3.(HapMap project). We found that the Asn/Asn genotype was
higher in DM controls (11.0%) than in DR subjects (2.3%),
suggesting a protective role against DR in general. In addition,
Asn/Asn was associated with an older age of onset of diabetes,
on average a six-year delay (Table 4). Therefore, Asn/Asn
might delay DM and protect against progression of DM to
NPDR.  The  Asn/Asn  genotype  was  not  associated  with
hypertension in our DM subjects, indicating that Asn/Asn
might  not  modulate  the  risk  of  DR  via  an  effect  on
hypertension. The frequency of Lys/Lys in PDR (56.9%) was
closer to that in DM controls (52.0%; p>0.017) than in NPDR
(75.7%;  p<0.017).  This  implies  that  the  pathological
mechanisms that lead to NPDR might be different from those
in  PDR.  Lys/Lys  might  contribute  a  role  in  the  early
breakdown of the blood retinal barrier (as may be the case in
NPDR) rather than vascular occlusion and neovascularization
(in the case of PDR).
In this study, we focused on a clinically well defined
diabetic population to explore the role of genetic factors in DR
progression. Each member of the control group lacked DR but
had  a  ≥10-year  history  of  diabetes.  According  to  the
Wisconsin  epidemiologic  study  of  diabetic  retinopathy
(WESDR), the 10-year incidence of DR was almost twice as
high as the four year incidence of DR in older onset diabetic
subjects (67% versus 34%). In insulin-dependent individuals
diagnosed  with  diabetes  before  the  age  of  30  years,  the
incidence of DR increased from 59% over 4 years to 89% over
10 years, and maintained a similar incidence of 86% over 14
years [25-27]. Thus, a 10-year duration of DM is a reasonable
criterion  for  selecting  controls  for  a  DR  genetic  study.
Diabetes  duration  and  glycemic  control  are  major
determinants  of  the  development  of  DR.  Our  results  also
showed that subjects who were younger at DM onset had a
higher risk of PDR than did subjects with later onset of DM
(OR=0.94; p=0.00001; Table 3).
ET-1 is implicated in some vascular diseases, including
the pathology of DR [28]. EDN1 has also been identified in
an early gestation human eye cDNA library and might be
important  for  eye  development  [29].  The  pathogenic
significance of the association of EDN1 Lys198Asn with DM
and DR remains unknown. Some studies suggested that the
Asn allele is associated with increased plasma concentrations
of ET-1 [9,10]. However, ET-1 levels in vitreous and aqueous
from DR patients were only elevated at the advanced stage of
DR (PDR), but decreased in the early stage (NPDR) [17,30].
ET-1 is synthesized from a 212-amino-acid precursor protein
(preproET-1) through multiple proteolytic steps. In the first
step, preproET-1 is cleaved by signal peptidase, resulting in
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TABLE 3. ODDS RATIO ADJUSTED BY MULTIVARIABLE LOGISTIC REGRESSION FOR THE ASSOCIATION WITH DIABETIC
RETINOPATHY IN PATIENTS WITH TYPE 2 DIABETES
Factors Adjusted OR Adjusted p value
DM versus DR
EDN1: Asn/Asn versus Lys/Lys+Lys/Asn 0.19 (0.07-0.53) 0.002
NPDR versus PDR
Age at onset of diabetes 0.94 (0.91-0.97) 0.00001
The relationship between diabetic retinopathy (DR) and its affected factors were tested by multivariable logistic regression
analysis.  The presence of DR was regarded as the dependent variable, and independent variables included genotype of EDN1,
eNOS, ITGA , and LTA, gender, age, age at onset of diabetes, HbA1c, therapy of insulin, hypertension, and hyperlipidemia. Only
items with p values <0.05 were listed. After adjustment for age, age at onset of diabetes and insulin therapy, etc,  EDN1  Asn/
Asn was the only independent protective factor for DR and younger onset age of diabetes was a significant risk factor for
nonproliferative diabetic retinopathy (NPDR) progressing to proliferative diabetic retinopathy (PDR).
TABLE 4. RELATIONSHIP BETWEEN EDN1GENOTYPE, AGE OF DIABETES MELLITUS ONSET, AND HYPERTENSION
Factors Lys/Lys Lys/Asn Asn/Asn p value
Number of patients 216 108 19
Age of diabetes mellitus onset 53.1+/-11.1 53.0+/-11.6 59.0+/-11.6 0.02
Hypertensive 143 (61.9%) 74 (32.0%) 14 (6.0%) 0.79
Nonhypertensive 73 (65.2%) 34 (30.4%) 5 (4.5%)
The onset age of diabetes mellitus (DM) and hypertension frequency were compared among different EDN1 genotypes in all
diabetic patients. The age of DM onset of patients with the Asn/Asn genotype was about six years later than patients with other
genotypes (p=0.02) and Lys198Asn genotype distributions were not different between hypertensive and nonhypertensive
subjects (p=0.79).the formation of proET-1. ProET-1 is then cleaved at the
paired dibasic amino acids by a furin-like enzyme to give rise
to 38-aminoacid big ET-1 or other intermediates. Big ET-1 is
subsequently  cleaved  at  Trp73-Val74  by  another
endopeptidase, endothelin converting enzyme, resulting in the
production  of  mature  ET-1  [31].  A  functional  in  vitro
expression study of EDN1 Lys198Asn found that neither ET-1
(bioactive  form)  nor  big  ET-1  (intermediate  polypeptide)
levels in the culture supernatant of the Asn-type transfected
cells were significantly changed compared to those of the Lys-
type transfected cells in three different cell lines: COS1 cells,
293  cells  and  human  umbilical  vein  endothelial  cells
(HUVECs)  [32].  Lys198Asn  is  located  near  the  carboxyl
terminal region, which is removed from prepro-ET-1 by the
proteolytic  action  of  the  furin-like  enzyme  during  the
processing of ET-1 [10,33]. This polymorphism may affect
the  processing  of  preproET-1  to  mature  ET-1  rather  than
modifying the gene expression or the stability of the mRNA.
So far there is no data on the functional consequence of the
Lys198Asn polymorphism on preproET-1. We hypothesized
that the protective effects of 198Asn on diabetes and DR might
not exert direct influence on ET-1 production. It could have
an impact on the processing of ET-1 or influence linkage
disequilibrium  with  other  polymorphisms  that  affect  the
production or conformation of the protein. Alterations in ET-1
level or function might affect the response to damage from
hyperglycemia and hypoxia in vascular endothelial and other
cell  types.  Another  EDN1  polymorphism,  a  dinucleotide
repeat in the 5′-untranslated region, did not have a major
impact on DR [19].
In conclusion, we identified the Asn/Asn genotype of
EDN1 as a genetic factor for delayed onset of DM and reduced
risk of DR in type 2 DM patients. Further studies in other DM
types and different ethnic populations should be performed.
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